Drug Topics

SEPTEMBER 5, 2024

As Medicare open enrollment begins, the NCPA is urging CMS to facilitate appropriate PBM contracting for pharmacies in the upcoming plan year.

Independent Pharmacies 206

Independent Pharmacies 206

Pharmacy Times

SEPTEMBER 5, 2024

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

149

149

STAT

SEPTEMBER 5, 2024

When a dye called tartrazine is added to food, it creates a bright yellow hue often associated with lemon-flavored candy. But when mixed with a little water and daubed on the skin of mice, the dye makes their skin nearly transparent.  Researchers reported the new use for the common food dye today in the journal Science. The technique creates a fresh opportunity for researchers to understand what is going on under the skin of a live animal, which could eventually allow them to study the inne

145

145

Fierce Pharma

SEPTEMBER 5, 2024

AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case. | AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case.

Insurance 145

Insurance 145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

SEPTEMBER 5, 2024

There is no significant impact on maternal or infant health outcomes when taking an additional iron supplement

145

145

STAT

SEPTEMBER 5, 2024

N ot only is Joseph Wright a physician, he’s the chief health equity officer for the American Academy of Pediatrics. So he was skeptical when, at his annual checkup in January, an alert popped up on his doctor’s computer screen. A calculator embedded in Wright’s health record had automatically pulled in his data, including the blood test he had done that morning.

140

140

STAT

SEPTEMBER 5, 2024

Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial product, a diabetes treatment targeting receptors of the amylin hormone, led to weight loss in early clinical trials. To achieve the weight loss, though, the drug had to be injected three times every day, making it “essentially a non-starter from a commercial point of view,” said David Kendall, an executive director at Amylin at the time.

139

139

Pharmacy Times

SEPTEMBER 5, 2024

Lauren Posteraro, PharmD, a pharmacist with AHN, discusses how misinformation and access to technology can contribute to vaccine hesitancy.

Vaccines 139

Vaccines 139

STAT

SEPTEMBER 5, 2024

A CRISPR-augmented stem cell transplant that protects healthy cells from the toxic effects of anti-cancer medicines has shown preliminary evidence that it can delay relapse in patients with an aggressive form of leukemia, its maker Vor Biopharma said Thursday.  In the early stage study, eight of 10 patients with high-risk acute myeloid leukemia remain in remission after receiving a transplant with the Vor therapy, called trem-cel, followed by maintenance treatment with intensified doses of

137

137

Fierce Healthcare

SEPTEMBER 5, 2024

SCAN Group is refreshing its visual identity, building its new look around honoring the "rebels with a cause" that founded the company and who continue to inspire its work. | SCAN Group is refreshing its visual identity, building its new look around honoring the "rebels with a cause" that founded the company and who continue to inspire its work.

134

134

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

SEPTEMBER 5, 2024

The number of U.S. kids who are using e-cigarettes has continued to tumble, new federal data show, prompting government health officials to declare an incremental victory in their fight against youth tobacco use. Around 6% of middle and high school students used vapes in 2024, down from 8% last year, and a record high of 20% in 2019, according to a survey released Thursday by the FDA and the CDC.

FDA 135

FDA 135

pharmaphorum

SEPTEMBER 5, 2024

A "small number" of AstraZeneca employees have been detained in China in an investigation into suspected data privacy and drug import breaches

133

133

STAT

SEPTEMBER 5, 2024

As former directors of the Centers for Disease Control and Prevention, we are deeply concerned that recent   recommendations  to pare back the CDC would cost lives and damage the economy. One misguided narrative is that the CDC should focus only on a “core mission” of combatting infectious diseases. In fact, the core mission of the CDC is to save lives and protect Americans from  all  health threats — not only infectious diseases but also cancer, environm

132

132

Pharmacy Times

SEPTEMBER 5, 2024

Previously, the FDA granted fast track designation to ABD-147 (Abdera Therapeutics Inc) for extensive stage small cell lung cancer.

FDA 132

FDA 132

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

SEPTEMBER 5, 2024

For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and targeted drugs have joined or replaced older, blunter tools like chemotherapy and radiation.  Children have been less fortunate.  Their tumors are far rarer than adult cancers and attract little interest from industry. Pediatric cancer researchers hoping to advance care have had to rely largely on repurposing newer drugs developed for adults — a limited strategy, as pediatric

Chemotherapy 130

Chemotherapy 130

Pharmacy Times

SEPTEMBER 5, 2024

Educators describe a project where they used TikTok to encourage students to develop innovative informatics and medication safety technologies for fun, engaging learning.

132

132

Fierce Healthcare

SEPTEMBER 5, 2024

Charles Jantzen, M.D., found himself swept up in the same current so many newly trained family physicians are in upon graduating from residency: employed by the health system where he previously tr | There is no single solution to this primary care shortage. Its complex drivers both shrink the entry pipeline and increase the terminal exodus.

128

128

Pharmacy Times

SEPTEMBER 5, 2024

The Center for Innovation & Value Research has released a final report recommending strategies to ensure health equity is integrated into health technology assessment, which can influence drug pricing and selection by payers, as well as patient access to drugs.

130

130

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

SEPTEMBER 5, 2024

Private equity firm New Mountain Capital merged three health tech companies in a multi-billion dollar deal to be a top player in the payment integrity market. | Private equity firm New Mountain Capital merged three health tech companies in a multi-billion dollar deal to be a top player in the payment integrity market.

126

126

STAT

SEPTEMBER 5, 2024

Let’s set the table for Sunday’s presentation of the lung cancer immunotherapy trial known as HARMONi-2.  Last June, Summit Therapeutics created a lot of buzz — and sent its stock surging — when it announced top-line results stating its experimental drug called ivonescimab delayed tumor progression significantly more than Merck’s Keytruda in a head-to-head Phase 3 study of patients with PD-L1 positive, advanced non-small cell lung cancer.

126

126

Fierce Pharma

SEPTEMBER 5, 2024

Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better chall | Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge AstraZeneca’s Tagrisso.

FDA 124

FDA 124

pharmaphorum

SEPTEMBER 5, 2024

Listen to the podcast interview with Manny Belabe from ArisGlobal as he discusses The Life Sciences Generative AI Council and its role in creating a sustainable technological future. Gain insights into the future of AI in life sciences.

124

124

Drug Topics

SEPTEMBER 5, 2024

CRS3123 is a novel, small molecule, antibiotic drug candidate that selectively inhibits 1 form of the bacterial methionyl-tRNA synthetase enzyme and is not affected by resistance to any existing classes of antibiotics.

123

123

STAT

SEPTEMBER 5, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Morning! Today, we talk about some highly anticipated data from Summit Therapeutics that could show how its bispecific antibody drug outperformed Keytruda in a head-to-head lung cancer trial. Also, positive data from Lilly on its weekly insulin, and we explore amylin as a target for obesity.

120

120

Fierce Pharma

SEPTEMBER 5, 2024

With dwindling funds after a prior snub from the FDA, ImmunityBio’s journey to bag approval for its Merck-rivaling bladder cancer drug Anktiva wasn’t easy. | The drugmaker laid off 20 employees as it attempts to recoup from dwindling funds during its Anktiva launch in bladder cancer.

FDA 119

FDA 119

STAT

SEPTEMBER 5, 2024

I coined the term “ Typo-gate ” to describe the misguided dustup Alnylam Pharmaceuticals executives instigated last Friday when they asserted cardiologist Sarah Cuddy made mistakes during her discussant’s talk following the presentation of the vutrisiran  HELIOS-B study results. The final verdict is the opposite. Alnylam was wrong, Cuddy was right.

Hospitals 119

Hospitals 119

Fierce Healthcare

SEPTEMBER 5, 2024

Elevance Health subsidiary WellPoint announced the company is debuting individual marketplace plans in Florida, Maryland and Texas. | Elevance Health subsidiary Wellpoint is debuting plans in three states for the 2025 coverage year.

119

119

STAT

SEPTEMBER 5, 2024

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. As Medicare telehealth flexibilities rapidly approach their expiration date , researchers from Cornell examined 2022 Medicare fee-for-service claims to understand how physician characteristics impacted telehealth use.

118

118

pharmaphorum

SEPTEMBER 5, 2024

EU General Court suspends decision to revoke the license for Advanz Pharma's primary biliary cholangitis drug Ocaliva.

116

116

STAT

SEPTEMBER 5, 2024

How effective is Summit Therapeutics’ lung cancer immunotherapy? Why are obesity drugmakers turning back to a two-decade-old idea? And how long will Elaine last as a new (official) co-host? We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We discuss the next big trend in obesity drug development — treatments that target the amylin hormone.

118

118

Fierce Pharma

SEPTEMBER 5, 2024

After handing over $30 million in criminal penalties last summer, Glenmark Pharmaceuticals has agreed to settle with the U.S. | Glenmark will pay the U.S. Department of Justice $25 million to resolve claims that it worked with other drugmakers to rig prices of the cholesterol med pravastatin. The case forms part of a larger antitrust probe implicating numerous manufacturers.

115

115

STAT

SEPTEMBER 5, 2024

A version of this essay first appeared in Jess Steier’s newsletter, “ Unbiased Science.” Fluoride is having a rough day in the court of public opinion. The National Toxicology Program (NTP), part of the Department of Health and Human Services, has released a  comprehensive study  titled “Monograph on the State of Science Concerning Fluoride Exposure and Neurodevelopment and Cognition,” and longtime fluoride foes argue that it includes a supposed

116

116

Drug Topics

SEPTEMBER 5, 2024

Findings were presented at the American Heart Association's Hypertension Scientific Sessions in Chicago, Illinois.

112

112